# This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma

Source: https://onco.cc/trials/nct07121946/  
OnCo record `nct07121946` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of LTZ-301 run by LTZ Therapeutics, Inc., now recruiting.

## Summary

This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma is a phase 1 interventional study registered as NCT07121946 by LTZ Therapeutics, Inc., with 42 participants planned, started 2026-01-29. Conditions recorded: Non-Hodgkin Lymphoma Refractory/ Relapsed, DLBCL - Diffuse Large B Cell Lymphoma, Mantle Cell Lymphoma (MCL), Follicular Lymphoma ( FL) and Marginal Zone Lymphoma (MZL). Interventions recorded: LTZ-301, LTZ-301 and LTZ-301.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07121946
- Phase: 1
- Setting: A Phase 1, Open-label, Multicenter Study of LTZ-301 in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma
- Sponsor: LTZ Therapeutics, Inc.
- Enrolled: 42

## Sources

- ClinicalTrials.gov NCT07121946: https://clinicaltrials.gov/study/NCT07121946

## Connected records

- cancers: [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/), [Follicular lymphoma](https://onco.cc/cancers/follicular-lymphoma/), [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)
- drugs: [LTZ-301](https://onco.cc/drugs/ltz-301/)
- companies: [LTZ Therapeutics](https://onco.cc/companies/ltz-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct07121946.json